Clinical Efficacy and Safety of Combination Therapy with Amlodipine and Olmesartan or Olmesartan /Hydrochlorothiazide Compound for Hypertension: A Prospective, Open-Label, and Multicenter Clinical Trial in China

Conclusions The combination therapy with OLM or OLM/HCTZ was well tolerated. The total incidence of adverse events (AEs) was 42.9% (n=176). Most of the AEs were mild (39.5%, n=162) in severity and not associated with the drugs (33.2%). In conclusion, the combination therapy with AML, OLM or OLM/HCTZ compound can significantly lowering BP safely and achieve high BP control rate in mild-to-moderate hypertension patients in China.
Source: Current Therapeutic Research - Category: Drugs & Pharmacology Source Type: research